Recombinant Human MICB Protein，His

MICB (MHC class I polypeptide-related sequence B) is an important protein involved in the immune response, particularly in the recognition and elimination of stressed or infected cells by cytotoxic T lymphocytes (CTLs). It belongs to the MHC class I family but is unique in that it is not involved in presenting conventional peptide antigens to T cells. Instead, MICB acts as a stress ligand, binding to NKG2D receptors on CTLs and natural killer (NK) cells, thus triggering an immune response against tumor or virally infected cells. Given its critical role in immune surveillance and potential involvement in various diseases, including cancer and viral infections, researchers have focused on the production and characterization of recombinant MICB protein. This recombinant protein can be utilized in various applications, including immunotherapy, where enhancing the immune response against tumors is desired. The study of recombinant MICB also extends to understanding its structural properties, interaction dynamics with immune receptors, and its potential as a biomarker for disease progression. Significant advancements in molecular cloning, protein expression, and purification techniques have facilitated the development of high-quality MICB protein, paving the way for both basic research and therapeutic innovations in immunology. As the scientific community continues to explore the functions and applications of MICB, it holds promise for novel strategies in combating cancers and infectious diseases, making it a focal point of ongoing immunological research.